^
    23h
    Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system. (PubMed, J Immunother Cancer)
    This study identifies a mechanism of OH2-induced PD-L1 expression in PCa and provides a versatile, targeted delivery platform that enables effective intravenous viro-immunotherapy, overcoming key translational barriers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    BS001
    1d
    OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    BS001 • BS006
    6d
    Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 (clinicaltrials.gov)
    P1, N=10, Recruiting, Johns Hopkins University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    NF1 (Neurofibromin 1)
    |
    Imlygic (talimogene laherparepvec)
    6d
    AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    sorafenib • azacitidine • etoposide IV • decitabine • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neupogen (filgrastim) • dexrazoxane
    7d
    A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=47, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027 | Initiation date: Oct 2025 --> Apr 2026 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Inqovi (decitabine/cedazuridine) • Neupogen (filgrastim)
    11d
    Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (clinicaltrials.gov)
    P1, N=5, Terminated, Rutgers, The State University of New Jersey | Active, not recruiting --> Terminated; slow accrual
    Trial termination • Tumor mutational burden
    |
    Vectibix (panitumumab) • Imlygic (talimogene laherparepvec)
    13d
    Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Imlygic (talimogene laherparepvec)
    19d
    A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov)
    P2/3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Leukine (sargramostim)
    19d
    Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer. (PubMed, JCO Precis Oncol)
    These results demonstrate OS advantage for maintenance treatment of adult females with newly diagnosed, advanced stage IIIb-IV ovarian cancer with HRP status and cTMB-H profile who are in complete response after debulking surgery and frontline platinum-based doublet chemotherapy.
    Clinical • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    Avastin (bevacizumab) • Vigil (gemogenovatucel-T)
    20d
    Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei (clinicaltrials.gov)
    P1, N=10, Recruiting, Oslo University Hospital
    New P1 trial • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    GNAS (GNAS Complex Locus) • CSF2 (Colony stimulating factor 2)
    |
    Tevimbra (tislelizumab-jsgr)
    22d
    PIVOT-006: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT (clinicaltrials.gov)
    P3, N=367, Active, not recruiting, CG Oncology, Inc. | Trial completion date: Jan 2030 --> Feb 2029 | Trial primary completion date: Jan 2028 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    cretostimogene grenadenorepvec (CG0070)
    1m
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=60, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor